| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 30 | 2023 | 2074 | 2.990 |
Why?
|
| Military Personnel | 7 | 2013 | 204 | 1.670 |
Why?
|
| Health Knowledge, Attitudes, Practice | 19 | 2021 | 905 | 1.550 |
Why?
|
| Health Personnel | 10 | 2018 | 541 | 1.360 |
Why?
|
| Smoking | 7 | 2015 | 1136 | 1.340 |
Why?
|
| Condoms | 8 | 2010 | 51 | 1.290 |
Why?
|
| Health Services Accessibility | 5 | 2025 | 649 | 1.230 |
Why?
|
| Smoking Cessation | 8 | 2016 | 209 | 1.110 |
Why?
|
| Motivational Interviewing | 7 | 2023 | 52 | 1.090 |
Why?
|
| Melanoma | 2 | 2024 | 966 | 1.020 |
Why?
|
| Sexual Behavior | 9 | 2013 | 251 | 1.020 |
Why?
|
| Substance-Related Disorders | 4 | 2023 | 492 | 1.000 |
Why?
|
| Perception | 7 | 2015 | 237 | 1.000 |
Why?
|
| Students | 5 | 2012 | 260 | 0.980 |
Why?
|
| Public Opinion | 2 | 2021 | 62 | 0.940 |
Why?
|
| Nigeria | 15 | 2021 | 81 | 0.940 |
Why?
|
| Medicare Part C | 9 | 2025 | 39 | 0.940 |
Why?
|
| Medication Adherence | 11 | 2025 | 343 | 0.850 |
Why?
|
| Adult | 55 | 2025 | 31958 | 0.850 |
Why?
|
| Texas | 21 | 2024 | 3713 | 0.840 |
Why?
|
| Health Education | 6 | 2010 | 230 | 0.840 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 157 | 0.760 |
Why?
|
| Immunotherapy | 2 | 2024 | 746 | 0.750 |
Why?
|
| Osteoarthritis | 1 | 2023 | 104 | 0.730 |
Why?
|
| Government | 1 | 2021 | 15 | 0.710 |
Why?
|
| Polypharmacy | 1 | 2021 | 40 | 0.710 |
Why?
|
| United States | 33 | 2025 | 11752 | 0.700 |
Why?
|
| Cross-Sectional Studies | 16 | 2025 | 3752 | 0.690 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2014 | 243 | 0.690 |
Why?
|
| Attitude to Health | 4 | 2007 | 264 | 0.680 |
Why?
|
| Young Adult | 24 | 2024 | 9912 | 0.660 |
Why?
|
| Delivery of Health Care | 3 | 2018 | 680 | 0.660 |
Why?
|
| Female | 70 | 2025 | 71818 | 0.650 |
Why?
|
| Male | 67 | 2025 | 66022 | 0.640 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 467 | 0.610 |
Why?
|
| Information Services | 1 | 2018 | 22 | 0.600 |
Why?
|
| Safe Sex | 3 | 2008 | 16 | 0.600 |
Why?
|
| AIDS Serodiagnosis | 2 | 2010 | 57 | 0.590 |
Why?
|
| Humans | 88 | 2025 | 134032 | 0.590 |
Why?
|
| Healthcare Disparities | 5 | 2025 | 480 | 0.580 |
Why?
|
| Universities | 4 | 2012 | 127 | 0.570 |
Why?
|
| Risk-Taking | 4 | 2012 | 105 | 0.560 |
Why?
|
| Socioeconomic Factors | 10 | 2025 | 920 | 0.560 |
Why?
|
| Middle Aged | 39 | 2025 | 29393 | 0.550 |
Why?
|
| Adolescent | 30 | 2024 | 20581 | 0.530 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2023 | 773 | 0.530 |
Why?
|
| Multiple Sclerosis | 3 | 2024 | 394 | 0.520 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2018 | 272 | 0.500 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 203 | 0.500 |
Why?
|
| Mental Disorders | 1 | 2023 | 887 | 0.490 |
Why?
|
| Logistic Models | 11 | 2017 | 1909 | 0.480 |
Why?
|
| Hypertension | 6 | 2023 | 1397 | 0.470 |
Why?
|
| Risk Factors | 14 | 2024 | 11162 | 0.470 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 346 | 0.450 |
Why?
|
| Health Behavior | 4 | 2015 | 404 | 0.440 |
Why?
|
| Sexually Transmitted Diseases | 2 | 2013 | 98 | 0.440 |
Why?
|
| Retrospective Studies | 24 | 2025 | 17507 | 0.440 |
Why?
|
| Counseling | 3 | 2014 | 240 | 0.410 |
Why?
|
| Atrial Fibrillation | 3 | 2025 | 695 | 0.400 |
Why?
|
| Videotape Recording | 2 | 2010 | 58 | 0.400 |
Why?
|
| Symphysiotomy | 1 | 2012 | 1 | 0.400 |
Why?
|
| Obstetric Labor Complications | 2 | 2012 | 98 | 0.390 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 448 | 0.390 |
Why?
|
| Consumer Health Information | 2 | 2012 | 30 | 0.370 |
Why?
|
| Surveys and Questionnaires | 11 | 2024 | 3997 | 0.370 |
Why?
|
| Educational Status | 3 | 2008 | 298 | 0.360 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2009 | 43 | 0.360 |
Why?
|
| Aged | 24 | 2025 | 21750 | 0.350 |
Why?
|
| Health Surveys | 2 | 2012 | 262 | 0.350 |
Why?
|
| Prejudice | 3 | 2009 | 39 | 0.350 |
Why?
|
| Risk Reduction Behavior | 2 | 2012 | 149 | 0.340 |
Why?
|
| Cardiovascular Diseases | 4 | 2025 | 2092 | 0.340 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 284 | 0.330 |
Why?
|
| Family Practice | 1 | 2010 | 92 | 0.330 |
Why?
|
| Focus Groups | 3 | 2024 | 212 | 0.330 |
Why?
|
| Anticoagulants | 2 | 2025 | 604 | 0.320 |
Why?
|
| Intention | 3 | 2022 | 97 | 0.320 |
Why?
|
| Attitude of Health Personnel | 4 | 2018 | 717 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2020 | 757 | 0.300 |
Why?
|
| Sexuality | 2 | 2005 | 13 | 0.300 |
Why?
|
| Cultural Competency | 1 | 2009 | 52 | 0.300 |
Why?
|
| Primary Health Care | 3 | 2019 | 803 | 0.290 |
Why?
|
| Antihypertensive Agents | 3 | 2020 | 410 | 0.290 |
Why?
|
| Mexican Americans | 2 | 2007 | 207 | 0.290 |
Why?
|
| Antitussive Agents | 1 | 2007 | 3 | 0.280 |
Why?
|
| Promethazine | 1 | 2007 | 5 | 0.280 |
Why?
|
| Codeine | 1 | 2007 | 23 | 0.280 |
Why?
|
| Opiate Substitution Treatment | 2 | 2024 | 30 | 0.280 |
Why?
|
| Educational Measurement | 2 | 2024 | 332 | 0.270 |
Why?
|
| Diabetes Mellitus | 4 | 2023 | 937 | 0.270 |
Why?
|
| Health Promotion | 2 | 2012 | 405 | 0.270 |
Why?
|
| Life Style | 2 | 2008 | 462 | 0.270 |
Why?
|
| Sex Factors | 5 | 2024 | 1387 | 0.260 |
Why?
|
| Psychology, Adolescent | 1 | 2006 | 35 | 0.260 |
Why?
|
| Cough | 1 | 2007 | 97 | 0.260 |
Why?
|
| Contraception Behavior | 1 | 2006 | 30 | 0.260 |
Why?
|
| Pharmaceutical Services | 2 | 2017 | 38 | 0.260 |
Why?
|
| Varenicline | 2 | 2016 | 14 | 0.250 |
Why?
|
| Bupropion | 2 | 2016 | 30 | 0.250 |
Why?
|
| Health Expenditures | 2 | 2024 | 117 | 0.250 |
Why?
|
| Proportional Hazards Models | 4 | 2024 | 1488 | 0.240 |
Why?
|
| Buprenorphine | 2 | 2024 | 100 | 0.230 |
Why?
|
| Multimorbidity | 1 | 2024 | 26 | 0.220 |
Why?
|
| Methadone | 1 | 2024 | 126 | 0.220 |
Why?
|
| Interviews as Topic | 2 | 2021 | 420 | 0.220 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 102 | 0.220 |
Why?
|
| Sex Offenses | 1 | 2005 | 48 | 0.220 |
Why?
|
| Markov Chains | 1 | 2024 | 99 | 0.220 |
Why?
|
| Rivaroxaban | 1 | 2024 | 55 | 0.220 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 128 | 0.220 |
Why?
|
| Drug Labeling | 2 | 2015 | 30 | 0.210 |
Why?
|
| Factor Xa Inhibitors | 1 | 2024 | 66 | 0.210 |
Why?
|
| Students, Pharmacy | 3 | 2024 | 71 | 0.210 |
Why?
|
| Pyridones | 1 | 2024 | 127 | 0.210 |
Why?
|
| Patient Acuity | 1 | 2023 | 67 | 0.210 |
Why?
|
| Prescriptions | 1 | 2023 | 43 | 0.200 |
Why?
|
| Education, Pharmacy | 1 | 2024 | 61 | 0.200 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 473 | 0.200 |
Why?
|
| HIV | 2 | 2018 | 195 | 0.200 |
Why?
|
| Demography | 2 | 2018 | 247 | 0.200 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2015 | 81 | 0.200 |
Why?
|
| Acetaminophen | 2 | 2015 | 101 | 0.200 |
Why?
|
| Middle East | 3 | 2012 | 34 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2024 | 475 | 0.190 |
Why?
|
| Drug Overdose | 1 | 2022 | 75 | 0.190 |
Why?
|
| Pyrazoles | 1 | 2024 | 329 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 563 | 0.180 |
Why?
|
| Health Status Disparities | 1 | 2024 | 249 | 0.180 |
Why?
|
| Sexual Partners | 2 | 2013 | 87 | 0.180 |
Why?
|
| Disease Transmission, Infectious | 1 | 2002 | 87 | 0.180 |
Why?
|
| Outpatients | 1 | 2023 | 274 | 0.180 |
Why?
|
| Hypertriglyceridemia | 1 | 2022 | 114 | 0.180 |
Why?
|
| Recurrence | 1 | 2024 | 1471 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 1997 | 42 | 0.170 |
Why?
|
| Diabetes Complications | 1 | 2022 | 206 | 0.170 |
Why?
|
| Medicare | 3 | 2024 | 465 | 0.170 |
Why?
|
| China | 1 | 2021 | 296 | 0.170 |
Why?
|
| Obesity | 4 | 2022 | 2444 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 703 | 0.170 |
Why?
|
| Chronic Pain | 1 | 2022 | 149 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 503 | 0.160 |
Why?
|
| Stroke | 2 | 2025 | 1075 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 4 | 2023 | 138 | 0.150 |
Why?
|
| Medicaid | 2 | 2019 | 254 | 0.150 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2023 | 226 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 1416 | 0.150 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 365 | 0.150 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 7207 | 0.150 |
Why?
|
| Self Efficacy | 2 | 2010 | 207 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 198 | 0.140 |
Why?
|
| Drug Combinations | 3 | 2020 | 284 | 0.140 |
Why?
|
| Prevalence | 5 | 2008 | 2683 | 0.140 |
Why?
|
| Nonprescription Drugs | 2 | 2015 | 54 | 0.140 |
Why?
|
| Registries | 1 | 2024 | 1576 | 0.140 |
Why?
|
| Infection Control | 2 | 2002 | 162 | 0.130 |
Why?
|
| Program Evaluation | 4 | 2019 | 457 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2022 | 700 | 0.130 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 27 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2024 | 3732 | 0.130 |
Why?
|
| Motivation | 2 | 2010 | 328 | 0.130 |
Why?
|
| Arabs | 1 | 2015 | 29 | 0.120 |
Why?
|
| Schizophrenic Psychology | 1 | 2016 | 85 | 0.120 |
Why?
|
| Heterosexuality | 3 | 2005 | 8 | 0.120 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 37 | 0.120 |
Why?
|
| Communication | 1 | 2000 | 542 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 45 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2023 | 5206 | 0.120 |
Why?
|
| Tobacco Products | 1 | 2015 | 72 | 0.120 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 98 | 0.120 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2015 | 116 | 0.120 |
Why?
|
| Hospitalization | 2 | 2020 | 1901 | 0.120 |
Why?
|
| Mental Health Services | 1 | 2018 | 278 | 0.110 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 154 | 0.110 |
Why?
|
| HIV Seropositivity | 2 | 2012 | 131 | 0.110 |
Why?
|
| Schizophrenia | 1 | 2016 | 332 | 0.100 |
Why?
|
| Immunologic Factors | 2 | 2024 | 184 | 0.100 |
Why?
|
| Psychotropic Drugs | 2 | 2018 | 130 | 0.100 |
Why?
|
| Weight Gain | 1 | 2016 | 412 | 0.100 |
Why?
|
| Telephone | 3 | 2019 | 127 | 0.100 |
Why?
|
| Cephalopelvic Disproportion | 1 | 2012 | 1 | 0.100 |
Why?
|
| Narcotic Antagonists | 2 | 2024 | 112 | 0.100 |
Why?
|
| Qualitative Research | 2 | 2024 | 639 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 490 | 0.100 |
Why?
|
| Southwestern United States | 1 | 2012 | 48 | 0.100 |
Why?
|
| Pakistan | 1 | 2012 | 94 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2025 | 727 | 0.100 |
Why?
|
| Africa South of the Sahara | 2 | 2010 | 129 | 0.100 |
Why?
|
| Time | 1 | 2012 | 101 | 0.100 |
Why?
|
| Behavior | 1 | 2012 | 75 | 0.100 |
Why?
|
| Jordan | 1 | 2012 | 8 | 0.100 |
Why?
|
| India | 1 | 2012 | 239 | 0.090 |
Why?
|
| Maternal Mortality | 1 | 2012 | 81 | 0.090 |
Why?
|
| Midwifery | 1 | 2012 | 41 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2025 | 13050 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2012 | 300 | 0.090 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2012 | 253 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 150 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1339 | 0.090 |
Why?
|
| Sociology, Medical | 1 | 2009 | 3 | 0.080 |
Why?
|
| Specialization | 1 | 2010 | 82 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 5475 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 287 | 0.080 |
Why?
|
| Data Collection | 2 | 2002 | 398 | 0.080 |
Why?
|
| Cesarean Section | 1 | 2012 | 402 | 0.080 |
Why?
|
| Career Choice | 1 | 2010 | 162 | 0.080 |
Why?
|
| Linear Models | 3 | 2018 | 723 | 0.080 |
Why?
|
| Financing, Personal | 1 | 2008 | 10 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1492 | 0.080 |
Why?
|
| Medicare Part D | 1 | 2008 | 17 | 0.070 |
Why?
|
| Bisexuality | 2 | 2005 | 13 | 0.070 |
Why?
|
| Physicians, Primary Care | 1 | 2010 | 98 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 320 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2019 | 6601 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2012 | 1338 | 0.070 |
Why?
|
| Androgen Antagonists | 1 | 2009 | 133 | 0.070 |
Why?
|
| Risk | 3 | 2015 | 835 | 0.070 |
Why?
|
| Homosexuality, Male | 2 | 2005 | 72 | 0.070 |
Why?
|
| Developing Countries | 1 | 2010 | 289 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2010 | 820 | 0.070 |
Why?
|
| Pharmacists | 2 | 2020 | 100 | 0.070 |
Why?
|
| Circumcision, Female | 1 | 2007 | 5 | 0.070 |
Why?
|
| Religion | 1 | 2007 | 51 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2009 | 271 | 0.070 |
Why?
|
| Gender Identity | 1 | 2007 | 72 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2008 | 135 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2007 | 47 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 129 | 0.070 |
Why?
|
| Obstetrics | 1 | 2010 | 240 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2012 | 1492 | 0.060 |
Why?
|
| Urban Population | 1 | 2008 | 243 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 1199 | 0.060 |
Why?
|
| Military Medicine | 1 | 2006 | 51 | 0.060 |
Why?
|
| Vancomycin | 1 | 2008 | 236 | 0.060 |
Why?
|
| Culture | 1 | 2006 | 73 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 560 | 0.060 |
Why?
|
| Public Housing | 1 | 2005 | 7 | 0.060 |
Why?
|
| Minority Groups | 1 | 2006 | 256 | 0.060 |
Why?
|
| Comorbidity | 3 | 2016 | 1625 | 0.060 |
Why?
|
| Pregnancy | 3 | 2012 | 7568 | 0.060 |
Why?
|
| Coronary Artery Bypass | 1 | 2008 | 537 | 0.060 |
Why?
|
| Patient Selection | 1 | 2008 | 735 | 0.050 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2008 | 459 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 1145 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2005 | 826 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 330 | 0.050 |
Why?
|
| Naloxone | 1 | 2022 | 51 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2002 | 79 | 0.050 |
Why?
|
| Health Status | 1 | 2024 | 412 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2022 | 1717 | 0.050 |
Why?
|
| Obesity, Abdominal | 1 | 2022 | 41 | 0.050 |
Why?
|
| Personnel, Hospital | 1 | 2002 | 34 | 0.050 |
Why?
|
| Prisons | 1 | 2001 | 13 | 0.050 |
Why?
|
| Mexico | 1 | 2022 | 190 | 0.050 |
Why?
|
| Inservice Training | 1 | 2002 | 56 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 118 | 0.050 |
Why?
|
| Poverty | 1 | 2005 | 438 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2025 | 509 | 0.040 |
Why?
|
| Hospitals, Teaching | 2 | 2002 | 114 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2002 | 143 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1624 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 574 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 765 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 209 | 0.040 |
Why?
|
| Universal Precautions | 1 | 1997 | 4 | 0.030 |
Why?
|
| SEER Program | 2 | 2009 | 224 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 1997 | 59 | 0.030 |
Why?
|
| Age Factors | 2 | 2019 | 2994 | 0.030 |
Why?
|
| Cultural Characteristics | 2 | 2007 | 43 | 0.030 |
Why?
|
| Smoking Prevention | 1 | 2016 | 38 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 2573 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 1997 | 233 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2015 | 37 | 0.030 |
Why?
|
| Self-Injurious Behavior | 1 | 2016 | 66 | 0.030 |
Why?
|
| Child | 3 | 2022 | 25816 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 377 | 0.030 |
Why?
|
| Incidence | 2 | 2015 | 3415 | 0.030 |
Why?
|
| Urban Health | 1 | 2014 | 79 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 77 | 0.030 |
Why?
|
| Social Stigma | 1 | 2014 | 85 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2019 | 1421 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 294 | 0.030 |
Why?
|
| Patient Participation | 1 | 2014 | 239 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 159 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 454 | 0.020 |
Why?
|
| Labor, Obstetric | 1 | 2012 | 97 | 0.020 |
Why?
|
| Overweight | 1 | 2014 | 387 | 0.020 |
Why?
|
| Self Report | 1 | 2014 | 553 | 0.020 |
Why?
|
| Clinical Competence | 2 | 2012 | 1062 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 815 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 3043 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2012 | 479 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2008 | 27 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2010 | 179 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2009 | 148 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2009 | 357 | 0.020 |
Why?
|
| Rural Population | 1 | 2010 | 280 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 444 | 0.020 |
Why?
|
| Sex Education | 1 | 2006 | 20 | 0.020 |
Why?
|
| Maternal Health Services | 1 | 2006 | 43 | 0.020 |
Why?
|
| Homicide | 1 | 2006 | 35 | 0.020 |
Why?
|
| Social Environment | 1 | 2006 | 126 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 1310 | 0.010 |
Why?
|
| Health Services Research | 1 | 2006 | 191 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2008 | 408 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 330 | 0.010 |
Why?
|
| Homosexuality, Female | 1 | 2003 | 3 | 0.010 |
Why?
|
| Length of Stay | 1 | 2008 | 1390 | 0.010 |
Why?
|
| Human Rights | 1 | 2002 | 24 | 0.010 |
Why?
|
| Fear | 1 | 2002 | 205 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2001 | 468 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 6604 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 1504 | 0.010 |
Why?
|